Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia

Abstract

A role for p53 in the in vivo progression of Friend virus-induced erythroleukemia has been suggested but not clearly defined. We developed a Friend virus-sensitive, p53-deficient mouse model to directly address the role of p53 in Friend erythroleukemia. When infected with the polycythemia-inducing strain of Friend virus (FVP), p53 null mice exhibited accelerated progression to erythroleukemia and accelerated death following diagnosis when compared to wild type mice. Confirmation that p53 mutations were required for disease progression was provided by sequence analysis of p53 transcripts in leukemic wild type and heterozygous mice. All transcripts evaluated had point mutations, deletions or insertions in the p53 gene. The ability to grow tumor colonies in vitro and derive cell lines was enhanced in FVP-infected p53 null animals. Although PU.1 oncogene overexpression is a common mutation observed in cell lines derived from Friend virus-infected p53 wild type mice, it was not a universal finding in cell lines derived from p53 null animals. Our data conclusively demonstrate that loss of p53 function is a requirement for progression of Friend erythroleukemia in vivo. Further, the data demonstrate that erythroleukemias arising in Friend virus-infected p53 null mice are biologically and genetically distinct from those that occur in wild type animals, suggesting that the temporal order of PU.1 and p53 mutations is an important parameter in the pathogenesis of leukemic development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Barnache S, Wendling F, Lacombe C, Denis N, Titeux M, Vainchenker W, Moreau-Gachelin F . 1998 Oncogene 16: 2989–2995

  • Ben-David Y, Bernstein A . 1991 Cell 66: 831–834

  • Ben David Y, Prideaux VR, Chow V, Benchimol S, Bernstein A . 1988 Oncogene 3: 179–185

  • Chow V, Ben-David Y, Bernstein A, Benchimol S, Mowat M . 1987 J. Virol. 61: 2777–2781

  • de Stanchina E, McCurrach ME, Zindy F, Shieh S-Y, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW . 1998 Genes Dev. 12: 2434–2442

  • Donehower LA . 1996 Semin. Cancer Biol. 7: 269–278

  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr. CA, Butel JS, Bradley A . 1992 Nature 356: 215–221

  • Hainaut P, Hollstein M . 2000 Adv. Cancer Res. 77: 81–137

  • Harvey M, McArthur MJ, Montgomery Jr. CA, Bradley A, Donehower LA . 1993 FASEB J. 7: 938–943

  • Hicks GG, Mowat M . 1988 J. Virol. 62: 4752–4755

  • Hofer E, Darnell Jr. JE . 1981 Cell 23: 585–593

  • Howard J, Ung Y, Adachi D, Ben-David Y . 1996 Cell Growth Differ. 7: 1651–1660

  • Howard JC, Yousefi S, Cheong G, Bernstein A, Ben-David Y . 1993 Oncogene 8: 2721–2729

  • Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA . 1994 Curr. Biol. 4: 1–7

  • Johnson P, Chung S, Benchimol S . 1993 Mol. Cell. Biol. 13: 1456–1463

  • Kelley LL, Hicks GG, Hsieh FF, Prasher JM, Green WF, Miller MD, Eide EJ, Ruley HE . 1998 Oncogene 17: 1119–1130

  • Khanna KK . 2000 J. Natl. Cancer Inst. 92: 795–802

  • Koury MJ, Park DJ, Martincic D, Horne DW, Kravtsov V, Whitlock JA, del Pilar Aguinaga M, Kopsombut P . 1997 Blood 90: 4054–4061

  • Lavigueur A, Bernstein A . 1991 Oncogene 6: 2197–2201

  • Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A . 1989 Mol. Cell. Biol. 9: 3982–3991

  • Li J-P, D'Andrea AD, Lodish HF, Baltimore D . 1990 Nature 343: 762–764

  • Li J-P, Hu H-O, Niu Q-T, Fang C . 1995 J. Virol. 69: 1714–1719

  • Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD . 1992 Cell 70: 923–935

  • Mager DL, Mak TW, Bernstein A . 1981 Proc. Natl. Acad. Sci. 78: 1703–1707

  • Moreau-Gachelin F, Ray D, de Both NJ, van der Feltz MJM, Tambourin P, Tavitian A . 1990 Leukemia 4: 20–23

  • Moreau-Gachelin F, Ray D, Mattei M-G, Tambourin P, Tavitian A . 1989 Oncogene 4: 1457–1462

  • Moreau-Gachelin F, Tavitian A, Tambourin P . 1988 Nature 331: 277–280

  • Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G, Briand P, Vainchenker W, Tavitian A . 1996 Mol. Cell. Biol. 16: 2453–2463

  • Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S . 1985 Nature 314: 633–636

  • Munroe DG, Peacock JW, Benchimol S . 1990 Mol. Cell. Biol. 10: 3307–3313

  • Munroe DG, Rovinski B, Bernstein A, Benchimol S . 1988 Oncogene 2: 621–624

  • Ney PA, D'Andrea AD . 2000 Blood 96: 3675–3680

  • Palmero I, Pantoja C, Serrano M . 1998 Nature 395: 125–126

  • Paul R, Schuetze S, Kozak SL, Kabat D . 1989 J. Virol. 63: 4958–4961

  • Prives C . 1998 Cell 95: 5–8

  • Quang CT, Wessely O, Pironin M, Beug H, Ghysdael J . 1997 EMBO. J. 16: 5639–5653

  • Ray D, Bosselut R, Ghysdael J, Mattei M-G, Tavitian A, Moreau-Gachelin F . 1992 Mol. Cell. Biol. 12: 4297–4304

  • Rovinski B, Munroe D, Peacock J, Mowat M, Bernstein A, Benchimol S . 1987 Mol. Cell. Biol. 7: 847–853

  • Ryan JJ, Danish R, Gottlieb CA, Clarke MF . 1993 Mol. Cell. Biochem. 13: 711–719

  • Schuetze S, Stenberg PE, Kabat D . 1993 Mol. Cell. Biol. 13: 5670–5678

  • Sherr CJ . 1998 Genes Dev. 12: 2984–2991

  • Shibuya T, Mak TW . 1982 Cell 31: 483–493

  • Silver J, Kozak C . 1986 J. Virol. 57: 526–533

  • Soussi T . 2001 Ann. NY Acad. Sci 121–139

  • Tambourin PE, Gallien-Lartigue O, Wendling F, Huaulme D . 1973 Br. J. Haematol. 24: 511–524

  • Wong KS, Li Y-J, Howard J, Ben-David Y . 1999 Oncogene 18: 5525–5534

  • Yamada T, Kondoh N, Matsumoto M, Yoshida M, Maekawa A, Oikawa T . 1997 Blood 89: 1383–1393

  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF . 1998 Genes Dev. 12: 2424–2433

Download references

Acknowledgements

We would like to thank Dr. Sandra Ruscetti, National Cancer Institute, Frederick, MD, USA for generally sharing reagents, protocols and advice regarding the study. This work was supported by an IRG from the American Cancer Society, The Primary Children's Medical Center Research Foundation, and NIH P50DK49219 (Center of Excellence in Molecular Hematology) to LL Kelley and NIH CA83984-01 to KSJ Elenitora-Johnson.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Linda L Kelley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prasher, J., Elenitoba-Johnson, K. & Kelley, L. Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia. Oncogene 20, 2946–2955 (2001). https://doi.org/10.1038/sj.onc.1204395

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204395

Keywords

This article is cited by

Search

Quick links